PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 15, 2026Cancer Medicine0 citationsOpen Access

Second Line Treatment Decisions in Advanced Non‐Small Cell Lung Cancer Using FMI

Second Line Treatment Decision as Per Standard of Care or Foundation Medicine in Patients With Locally Advanced or Metastatic Non‐Small Cell Lung Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

FRF. G. RojoEFEnriqueta FelipÓVÓscar Vidal

Discussion

Loading...

Member takes

Overview

This analysis demonstrates how FMI genomic profiling modifies treatment in patients with advanced NSCLC, suggesting improved outcomes.

Key Points

  • This research aims to evaluate the impact of Foundation Medicine (FMI) genomic profiling on treatment decisions for advanced non-small cell lung cancer (NSCLC).
  • Utilized FMI genomic profiling data to assess treatment pathways.
  • Compared treatment decisions between standard of care (SOC) and FMI recommendations.
  • Directed eligible patients towards clinical trials based on their genomic data.
  • Clinicians modified management strategies for several NSCLC patients.
  • FMI identified actionable mutations that SOC approaches missed.
  • The findings highlight FMI's potential to enhance personalized medicine in NSCLC treatment.

Cite This Study

Rojo et al. (2026) studied this question.

synapsesocial.com/papers/69df2ba0e4eeef8a2a6b09fbhttps://doi.org/10.1002/cam4.71790
View Full Paper
Ask AI
Bookmark
Share